Anthra, Medeva deal

MDV acquired exclusive U.S. marketing rights to Anthra's AD32 anthracycline derivative for

Read the full 129 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE